Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islatravir once-monthly for HIV PrEP
NCT04003103Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2019
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Sep 2019; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04003103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003103.